CoChat

Interleukin 12: still a promising candidate for tumor immunotherapy?

Open access
Lasek, Witold, Zagożdżon, Radosław, Jakobisiak, Marek · 2014 · Cancer Immunology Immunotherapy

The DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.

Abstract

Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-014-1523-1

Cites

362 of 362 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 An overview of the biological properties of IL-12 contributing to the antitumor activity of this cytokine (see the text for details). APC antigen-presenting cell, NK natural killer cell, Tc cytotoxic T lymphocyte, Th T helper lymphocyte, IP-10 interferon-inducible protein 10, MIG monokine induced by interferon γ
Fig. 1 An overview of the biological properties of IL-12 contributing to the antitumor activity of this cytokine (see the text for details). APC antigen-presenting cell, NK natural killer cell, Tc cytotoxic T lymphocyte, Th T helper lymphocyte, IP-10 interferon-inducible protein 10, MIG monokine induced by interferon γCC BY · PubMed Central
Fig. 2 Number of IL-12-based clinical trials in the field of tumor immunotherapy that have been started since 1996 and have been registered in ClinicalTrials.gov database (http://www.clinicaltrials.gov). The histogram comprises studies in which IL-12 was used alone or in combination, either as a main therapeutic or administered in an adjuvant setting including gene therapy
Fig. 2 Number of IL-12-based clinical trials in the field of tumor immunotherapy that have been started since 1996 and have been registered in ClinicalTrials.gov database (http://www.clinicaltrials.gov). The histogram comprises studies in which IL-12 was used alone or in combination, either as a main therapeutic or administered in an adjuvant setting including gene therapyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

5 retracted

Show all 362 references

Cited by

See all 550

Metadata

Authors
Lasek, W., Zagożdżon, R., & Jakobisiak, M.
Affiliations
Medical University of Warsaw (PL)
Corresponding author
Lasek, Witold
Venue
Cancer Immunology Immunotherapy
Published
2014-02-11
Volume
63
Issue
5
Pages
419-435
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2025459290
Cited by
495
References
354
Citations by year
2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
FWCI
3.03
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Immunotherapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
European Commission (316254)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Keywords
IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
MeSH terms
Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin 12: still a promising candidate for tumor immunotherapy? https://app.cochat.ai/papers/10.1007/s00262-014-1523-1
The paper
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014). Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunology Immunotherapy. https://doi.org/10.1007/s00262-014-1523-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.